Effectiveness Questioned: Study Finds That Paxlovid Fails To Reduce Long COVID Risk

Researchers at UCSF have discovered an unexpectedly high rate of COVID rebound following treatment with Paxlovid. A group of scientists from the University of California, San Francisco, discovered that Paxlovid (Nirmatrelvir-ritonavir) was ineffective in lowering the chances of vaccinated, non-hosp

Related Keywords

San Francisco ,California ,United States ,Carmen Isasi ,Steveng Deeks ,Noahd Peyser ,Markj Pletcher ,Matthew Durstenfeld ,Jeffreye Olgin ,Timothyj Henrich ,Feng Lin ,Michaelj Peluso ,Matthews Durstenfeld ,Alexisl Beatty ,Gregorym Marcus ,University Of California ,Melinda Gates Foundation ,Eureka Research Platform ,Outcomes Research Institute ,Science Study ,Patient Centered Outcomes Research Institute ,